CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously ...
Phase 2
Hamilton, Ontario, Canada and 4 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Toronto, Ontario, Canada and 145 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Phase 1, Phase 2
Toronto, Ontario, Canada and 48 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Toronto, Ontario, Canada and 59 other locations
phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma...
Phase 1, Phase 2
Toronto, Ontario, Canada and 24 other locations
1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...
Phase 1, Phase 2
Toronto, Ontario, Canada and 12 other locations
is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple...
Phase 1
Toronto, Ontario, Canada and 9 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Toronto, Canada and 126 other locations
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...
Phase 1
Hamilton, Ontario, Canada and 37 other locations
as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts:...
Phase 1
Toronto, Ontario, Canada and 14 other locations
Clinical trials
Research sites
Resources
Legal